Live Chat

交易 Vir Biotechnology VIR

出售
 購買

VirBiotechnology實時圖表

5m 15m 30m 1h 4h 1d 1w

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%)： 開倉 高 低

最新新聞

Christine Voong 2025 Feb 21, 10:35

日產汽車合併破局，特斯拉投資傳聞升溫，美國產能佈局受關注

Christine Voong 2025 Feb 21, 06:40

國際原油價格走勢受供應風險推動，美國原油庫存增加影響市場預期

Christine Voong 2025 Feb 21, 05:00

阿里巴巴集團：阿里巴巴股價飆升三年新高，阿里巴巴港股勁揚帶動中國科技股走強

Christine Voong 2025 Feb 21, 03:45

日圓匯率受通膨數據推升，美元兌日圓跌破150，美元走勢疲弱

Space.Xia 2025 Feb 20, 16:00

Figure AI推出Helix模型：AI機器人技術革新引領投資熱潮

Space.Xia 2025 Feb 20, 16:00

AI雲計算驅動新一輪投資熱潮，三大電信商市值飆升

Christine Voong 2025 Feb 20, 09:30

比特幣價格走勢持穩，加密貨幣市場觀望美國關稅政策與美聯儲利率決策影響

Christine Voong 2025 Feb 20, 08:20

黃金價格走勢亞洲盤中創新高！避險需求推動上漲，美元走勢強勁壓制漲幅

聯絡方式

點差

0.07

點差(%)

0.7330 %

槓桿

1:10

隔夜利息（買入）

-0.0597 %

隔夜利息（賣出）

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期一

14:31 - 20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

1317980416

流通股份

137720000

收益日期（下一個）

0000-00-00

現金殖利率 

除息日

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-3.93

了解有關此金融工具的詳細資訊

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相關工具

資產
出售
購買
更改(%)：

立即交易

立即交易

立即交易

立即交易
查看所有金融工具
Trustpilot
Live Chat